A novel model of cancer drug resistance: oncosomal release of cytotoxic and antibody-based drugs

35Citations
Citations of this article
40Readers
Mendeley users who have this article in their library.

Abstract

Extracellular vesicles (EVs), such as exosomes or oncosomes, often carry oncogenic molecules derived from tumor cells. In addition, accumulating evidence indicates that tumor cells can eject anti-cancer drugs such as chemotherapeutics and targeted drugs within EVs, a novel mechanism of drug resistance. The EV-releasing drug resistance phenotype is often coupled with cellular dedifferentiation and transformation in cells undergoing epithelial-mesenchymal transition (EMT), and the adoption of a cancer stem cell phenotype. The release of EVs is also involved in immunosuppression. Herein, we address different aspects by which EVs modulate the tumor microenvironment to become resistant to anticancer and antibody-based drugs, as well as the concept of the resistance-associated secretory phenotype (RASP).

Cite

CITATION STYLE

APA

Eguchi, T., Taha, E. A., Calderwood, S. K., & Ono, K. (2020, March 1). A novel model of cancer drug resistance: oncosomal release of cytotoxic and antibody-based drugs. Biology. MDPI AG. https://doi.org/10.3390/biology9030047

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free